A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
Not yet recruiting · NCT06980207 · Registry updated 2025-05-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 | Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disorders | Not yet recruiting | Phase 1 | 2025-05-20 | NCT06980207 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Luye Pharma Group Ltd. | 14 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Mental Health Center | Shanghai | China | 22 |